News – Oxford Sciences Innovation

Updates

Oxford Sciences Innovation @OSI_Updates·

We're excited to share the news that @YASAMotors has been acquired by @MercedesBenzUK.

This acquisition will further accelerate the positive impact of YASA's world-leading technology - supporting the adoption of electric vehicles globally.

#electricvehicles #oxford #automotive

Financial Times@FT

Mercedes buys UK start-up Yasa as it steps up electric transition https://on.ft.com/3zq1QPK

Reply on Twitter 1418498777107808261 Retweet on Twitter 14184987771078082614 Like on Twitter 14184987771078082616 Twitter 1418498777107808261

Oxford Sciences Innovation @OSI_Updates·

22 Jul

Exciting news from Circadian Therapeutics!
Circadian Therapeutics and ARQUIMEA have signed an agreement for the co-development of molecules as an innovative treatment for nervous system diseases such as ALS, Parkinson’s, and Alzheimer’s disease.
@sleepscientist1 #healthcare

Reply on Twitter 1418214687439654915 Retweet on Twitter 14182146874396549155 Like on Twitter 14182146874396549159 Twitter 1418214687439654915

Oxford Sciences Innovation @OSI_Updates·

22 Jul

Fantastic to see @UniofOxford ranked as the top UK university for life sciences spinouts, with a special mention of OSI portfolio company @EvOx_Ltd!

https://www.beauhurst.com/blog/top-universities-life-sciences-spinouts/

#lifesciences #innovation #science @OxUInnovation

Reply on Twitter 1418185968465719305 Retweet on Twitter 14181859684657193055 Like on Twitter 141818596846571930527 Twitter 1418185968465719305

Stay up to date with the OSI community

Perspectum Launches New Clinical Study to Investigate Integrated Diagnostics to Enable Precision Medicine for Liver Cancer Patients

OQC delivers the UK’s first Quantum Computing as-a-Service

Introducing our newest Scientist in Residence: Sarah Leonard

UK Science Minister Amanda Solloway MP launches First Light Fusion’s maiden ‘Big Gun’ fusion campaign

DNV verifies Brill Power’s new battery management system technology

Oxford University academics recognised in Queen’s Birthday Honours – including Vaccitech co-founders

Nucleome Therapeutics has published its novel 3D genome analysis method, a significant advancement in the field, in the journal Nature

Caristo Diagnostics’ technology can predict heart attacks nearly a decade in advance – it is now in use on Harley street and will soon be available on the NHS

PepGen Strengthens Leadership Team with SVP of Chemistry, Manufacturing & Controls and VP of Finance Appointments

Nucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its Board

ONI Welcomes Dr Tyler Ralston as Chief Technology Officer

Welcome to the portfolio Ivy Farm Technologies! Find out why Ivy Farm is the future for meat lovers, animal lovers and our planet.

First Light Fusion installs UK’s biggest two-stage hyper-velocity gas gun to advance its projectile fusion technology.

Perspectum partners in a new study in singapore for the early detection of liver cancer using precision medicine

Vaccitech announces closing of $110.5 million initial public offering – the 1st IPO for the OSI portfolio!

Vaccitech announces pricing of initial public offering – the 1st IPO for the OSI portfolio!

Perspectum’s new study shows measurable organ impairment in Long COVID patients

Alexis Dormandy has joined the UK government’s new expert council formed to maximise UK investment offer

OSI UPDATES: SPRING 2021 NEWSLETTER

Oxford Endovascular Ltd raises $10m to develop its origami engineered medical device to prevent brain haemorrhage

Quantum Computing Breakthrough Shows Blueprint for Scalable Future

Perspectum research links high liver fat to increased risk of hospitalization in COVID-19 patients with obesity

Meet the Founders: Cheerag Shirodaria, CEO and Charalambos Antoniades, CSO, Caristo Diagnostics

Caristo Diagnostics announces EU approval for AI technology which can predict heart attacks years in advance

Vaccitech appoints Joseph Scheeren, PharmD, to its Board of Directors

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results

Meet Oxford’s Female Founders & CEOs – watch the recorded event!

International Women’s Day: Meet Oxford’s Female Founders

SpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor

MoA Tech appoints Virginia Corless as CEO

Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings

Vaccitech appoints two independent board directors

Genomics Plc completes oversubscribed $30m funding round

PepGen Announces Formation of Scientific Advisory Board

Welcome to the portfolio: T-Cypher Bio

EVOX THERAPEUTICS COMPLETES £69.2 MILLION SERIES C FINANCING

£2.5M for intelligent battery technology start up, Brill Power

SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman

OSI UPDATES: WINTER 2021 NEWSLETTER

Professor Jerry Chittenden joins First Light Fusion’s Advisory Board

PepGen appoints James McArthur, Ph.D., as President and Chief Executive Officer

Scenic Biotech Appoints Dr. Philippe Dro as Independent Chairman

First patient receives Vaccitech’s VTP-300 in a Phase 1b/2a clinical trial. An experimental immunotherapy for chronic HBV, a global health problem affecting over 250 million people

Introducing our first Entrepreneur in Residence from Biopharma: Damian Crowther

John McHutchison joins the board of Evox Therapeutics

Perspectum’s CoverScan MD approved by the UK’s MHRA – the world’s first integrated imaging service capable of mapping the impact of COVID-19 on the body

Ex-Centrica and BP boss Iain Conn joins Oxford Flow board

OQC lab takes delivery of first Proteox worldwide – a significant milestone to building a quantum-powered future

OQC state-of-the-art quantum laboratory opens

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies

Ultromics’ first-of-a-kind AI solution to help clinicians diagnose coronary artery disease from echiocardiograms in a matter of minutes approved by the FDA

Bodle Technologies Secures Series A Funding Extension

Perspectum issued CPT® Codes for LiverMultiScan® by the American Medical Association to help Drs diagnose and treat liver disease

Clean nuclear: Oxford start-up 10 years ahead of government targets in race to build fusion plant

LifeArc co-leads £6 million funding in DJS Antibodies

MERRY CHRISTMAS FROM ALL THE TEAM AT OSI

Meet the Founder: Sumi Biswas, CEO of SpyBiotech

PepGen raises $45M in Series A funding, led by RA Capital

HEXR launches smartphone fitting app: Bespoke, 3D printed helmets now accessible to millions

Software Ate the World, and Soon It Will Write Itself – Wall Street Journal article by Diffblue

Counterfeit drugs and illegitimate vaccines, both costly and deadly, could be a thing of the past with new breakthrough testing technology from Proxisense and Oxford University

Refeyn Closes Series A Funding Round, led by Northpond Ventures

The Backstory: Vaccitech and its role in co-inventing the Oxford COVID-19 vaccine

BREAKTHROUGH FOR OXFORD’S COVID VACCINE, CO-INVENTED BY OSI PORTFOLIO COMPANY VACCITECH

Evox Therapeutics launch strategic collaboration with Oxford University to accelerate development of exosome therapies for rare diseases

Mind Foundry raises an additional $13.6 million in Series A funding led by Aioi Nissay Dowa Insurance

OSI UPDATES: AUTUMN 2020 NEWSLETTER

The Backstory: Base Genomics and their mission to defeat cancer through early diagnosis

Oxford Sciences Innovation announces the sale of Base Genomics to Exact Sciences

Vaccitech expands management team with hires including CMO and CFO

Notice of Annual General Meeting

Fusion energy can be the most cost competitive source of baseload power, at the same level as renewables

Oxford Sciences Innovation appoints Alexis Dormandy as CEO

Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

3 portfolio companies win the NHSX AI in Healthcare Award

SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19

Biocentury feature: OSI leverages foundational deal with Oxford to build its life sciences portfolio

Celebrating five years of OSI and Oxford’s history of innovation